Cargando…
Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal
Neoadjuvant chemotherapy (NAC) significantly improved the prognosis of patients with locally advanced resectable gastric cancer but, despite important progresses, relapse-related death remains a major challenge. Therefore, it appears crucial to understand which patients will benefit from peri-operat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414610/ https://www.ncbi.nlm.nih.gov/pubmed/34484429 http://dx.doi.org/10.1177/17588359211029559 |
_version_ | 1783747813010571264 |
---|---|
author | Gervaso, Lorenzo Pellicori, Stefania Cella, Chiara A. Bagnardi, Vincenzo Lordick, Florian Fazio, Nicola |
author_facet | Gervaso, Lorenzo Pellicori, Stefania Cella, Chiara A. Bagnardi, Vincenzo Lordick, Florian Fazio, Nicola |
author_sort | Gervaso, Lorenzo |
collection | PubMed |
description | Neoadjuvant chemotherapy (NAC) significantly improved the prognosis of patients with locally advanced resectable gastric cancer but, despite important progresses, relapse-related death remains a major challenge. Therefore, it appears crucial to understand which patients will benefit from peri-operative treatment. Biomarkers such as human epidermal growth factor receptor-2 (HER2), microsatellite instability (MSI), and Epstein-Barr Virus (EBV) have been widely studied; however, they do not yet guide the choice of perioperative treatment in clinical practice. We performed a narrative review, including 23 studies, addressing the value of tissue- or blood-based biomarkers in the neoadjuvant setting. Ten studies (43.5%) were prospective, and more than half were conducted in East-Asia. Biomarkers were evaluated only post-NAC (on surgical samples or blood) in seven studies (30.4%), only pre-NAC (on endoscopic specimens or blood) in 10 studies (43.5%), and both pre- and post-NAC (26.1%) in six studies. Among the high variety of investigated biomarkers, some of these including MSI-H or enzymatic profile (as TS, UGT1A1, MTHFR, ERCC or XRCC) showed promising results and deserve to be assessed in methodologically sound clinical trials. The identification of molecular biomarkers in patients treated with NAC for locally advanced resectable gastric or EGJ cancer remains crucial. |
format | Online Article Text |
id | pubmed-8414610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-84146102021-09-04 Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal Gervaso, Lorenzo Pellicori, Stefania Cella, Chiara A. Bagnardi, Vincenzo Lordick, Florian Fazio, Nicola Ther Adv Med Oncol Review Neoadjuvant chemotherapy (NAC) significantly improved the prognosis of patients with locally advanced resectable gastric cancer but, despite important progresses, relapse-related death remains a major challenge. Therefore, it appears crucial to understand which patients will benefit from peri-operative treatment. Biomarkers such as human epidermal growth factor receptor-2 (HER2), microsatellite instability (MSI), and Epstein-Barr Virus (EBV) have been widely studied; however, they do not yet guide the choice of perioperative treatment in clinical practice. We performed a narrative review, including 23 studies, addressing the value of tissue- or blood-based biomarkers in the neoadjuvant setting. Ten studies (43.5%) were prospective, and more than half were conducted in East-Asia. Biomarkers were evaluated only post-NAC (on surgical samples or blood) in seven studies (30.4%), only pre-NAC (on endoscopic specimens or blood) in 10 studies (43.5%), and both pre- and post-NAC (26.1%) in six studies. Among the high variety of investigated biomarkers, some of these including MSI-H or enzymatic profile (as TS, UGT1A1, MTHFR, ERCC or XRCC) showed promising results and deserve to be assessed in methodologically sound clinical trials. The identification of molecular biomarkers in patients treated with NAC for locally advanced resectable gastric or EGJ cancer remains crucial. SAGE Publications 2021-09-01 /pmc/articles/PMC8414610/ /pubmed/34484429 http://dx.doi.org/10.1177/17588359211029559 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Gervaso, Lorenzo Pellicori, Stefania Cella, Chiara A. Bagnardi, Vincenzo Lordick, Florian Fazio, Nicola Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal |
title | Biomarker evaluation in radically resectable locally advanced gastric
cancer treated with neoadjuvant chemotherapy: an evidence
reappraisal |
title_full | Biomarker evaluation in radically resectable locally advanced gastric
cancer treated with neoadjuvant chemotherapy: an evidence
reappraisal |
title_fullStr | Biomarker evaluation in radically resectable locally advanced gastric
cancer treated with neoadjuvant chemotherapy: an evidence
reappraisal |
title_full_unstemmed | Biomarker evaluation in radically resectable locally advanced gastric
cancer treated with neoadjuvant chemotherapy: an evidence
reappraisal |
title_short | Biomarker evaluation in radically resectable locally advanced gastric
cancer treated with neoadjuvant chemotherapy: an evidence
reappraisal |
title_sort | biomarker evaluation in radically resectable locally advanced gastric
cancer treated with neoadjuvant chemotherapy: an evidence
reappraisal |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414610/ https://www.ncbi.nlm.nih.gov/pubmed/34484429 http://dx.doi.org/10.1177/17588359211029559 |
work_keys_str_mv | AT gervasolorenzo biomarkerevaluationinradicallyresectablelocallyadvancedgastriccancertreatedwithneoadjuvantchemotherapyanevidencereappraisal AT pellicoristefania biomarkerevaluationinradicallyresectablelocallyadvancedgastriccancertreatedwithneoadjuvantchemotherapyanevidencereappraisal AT cellachiaraa biomarkerevaluationinradicallyresectablelocallyadvancedgastriccancertreatedwithneoadjuvantchemotherapyanevidencereappraisal AT bagnardivincenzo biomarkerevaluationinradicallyresectablelocallyadvancedgastriccancertreatedwithneoadjuvantchemotherapyanevidencereappraisal AT lordickflorian biomarkerevaluationinradicallyresectablelocallyadvancedgastriccancertreatedwithneoadjuvantchemotherapyanevidencereappraisal AT fazionicola biomarkerevaluationinradicallyresectablelocallyadvancedgastriccancertreatedwithneoadjuvantchemotherapyanevidencereappraisal |